Skip to content
★ Sign in to follow
엔에

엔에이치기업인수목적23호 Stock: price and insider trades · South Korea

No insider purchase over the last 90 days. The latest, by 엣데이터, was filed 04 Feb 2025.

엔에이치기업인수목적23호: what insiders have been doing

엔에이치기업인수목적23호 is a listed company. Its insiders report their share dealings to DART (FSS). 엔에이치기업인수목적23호 has had no insider filing for more than a year; the last one goes back to 4 February 2025.

Looking back to 2022, when coverage begins, insiders filed 8 purchases and no sales.

Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
8
Thresholds
n/a
Buy Volume
n/a
8 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
엣데이터1 buy

Financial data

· cache

Last declaration on 4 February 2025
Declarations8 total
  • ▲
    대량보유자Executives
    0DART
    598,000 sharesKRXDART:20250204000433
    Canonical exit: 24 Apr 2025 (T+90)
  • ▲
    Related company / holdingExecutives
    0DART
    83,462 sharesKRXDART:20241030000116
    Canonical exit: 21 Jan 2025 (T+90)
  • ▲
    Related company / holdingExecutives
    0DART
    394,088 sharesKRXDART:20241022000117
    Canonical exit: 13 Jan 2025 (T+90)
  • ▲
    Related company / holdingExecutives
    0DART
    394,088 sharesKRXDART:20230522000338
    Canonical exit: 15 Aug 2023 (T+90)
  • ▲
    Executives
    0DART
    1,000,000 sharesShareKRXDART:20220705000038
    Canonical exit: 26 Sept 2022 (T+90)
  • ▲
    Related company / holdingExecutives(filed)
    0DART
    394,088 sharesKRXDART:20220705000037
    Canonical exit: 3 Oct 2022 (T+90)
  • ▲
    Related company / holdingExecutives(filed)
    0DART
    394,088 sharesKRXDART:20220630000669
    Canonical exit: 28 Sept 2022 (T+90)
  • ▲
    Related company / holdingExecutives(filed)
    0DART
    394,088 sharesKRXDART:20220629000404
    Canonical exit: 27 Sept 2022 (T+90)

8 of 8 declarations

About 엔에이치기업인수목적23호

NH Special Purpose Acquisition Company No. 23 is a company listed on the XKRX market.